Progyny, Inc. Expected to Earn FY2025 Earnings of $0.62 Per Share (NASDAQ:PGNY)

Progyny, Inc. (NASDAQ:PGNY) – Leerink Partnrs dropped their FY2025 EPS estimates for Progyny in a report released on Wednesday, September 18th. Leerink Partnrs analyst M. Cherny now forecasts that the company will post earnings of $0.62 per share for the year, down from their previous forecast of $0.86. Leerink Partnrs currently has a “Hold” rating on the stock. The consensus estimate for Progyny’s current full-year earnings is $0.64 per share. Leerink Partnrs also issued estimates for Progyny’s FY2027 earnings at $1.41 EPS.

Progyny (NASDAQ:PGNY) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $0.17 EPS for the quarter, hitting the consensus estimate of $0.17. The firm had revenue of $304.09 million during the quarter, compared to the consensus estimate of $305.32 million. Progyny had a return on equity of 11.97% and a net margin of 5.54%. The company’s quarterly revenue was up 8.8% compared to the same quarter last year. During the same period in the prior year, the business posted $0.15 earnings per share.

PGNY has been the subject of a number of other reports. Canaccord Genuity Group reduced their price objective on shares of Progyny from $24.00 to $18.00 and set a “hold” rating for the company in a research report on Friday, September 20th. Canaccord Genuity Group lowered Progyny from a “buy” rating to a “hold” rating and reduced their target price for the company from $37.00 to $24.00 in a report on Wednesday, August 7th. Jefferies Financial Group decreased their price target on Progyny from $31.00 to $24.00 and set a “buy” rating for the company in a research report on Thursday, September 19th. Truist Financial cut their price objective on Progyny from $33.00 to $26.00 and set a “buy” rating on the stock in a research report on Thursday, September 19th. Finally, JPMorgan Chase & Co. decreased their target price on Progyny from $31.00 to $22.00 and set an “overweight” rating for the company in a research report on Thursday, September 19th. Seven analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $27.73.

Progyny Price Performance

NASDAQ PGNY opened at $17.15 on Monday. The company has a fifty day moving average price of $23.59 and a 200-day moving average price of $28.32. The firm has a market cap of $1.63 billion, a price-to-earnings ratio of 28.11, a PEG ratio of 1.97 and a beta of 1.45. Progyny has a 1 year low of $13.93 and a 1 year high of $42.08.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Quarry LP boosted its stake in Progyny by 1,900.0% during the second quarter. Quarry LP now owns 880 shares of the company’s stock valued at $25,000 after buying an additional 836 shares during the period. TFC Financial Management Inc. bought a new stake in shares of Progyny during the 1st quarter valued at about $42,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Progyny during the second quarter worth about $44,000. Financial Management Professionals Inc. bought a new position in shares of Progyny in the first quarter worth approximately $52,000. Finally, Cambridge Trust Co. purchased a new stake in Progyny in the first quarter valued at approximately $95,000. 94.93% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Progyny news, Director Cheryl Scott sold 1,462 shares of the business’s stock in a transaction on Friday, June 28th. The shares were sold at an average price of $28.39, for a total transaction of $41,506.18. Following the sale, the director now owns 10,098 shares of the company’s stock, valued at approximately $286,682.22. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, President Michael E. Sturmer sold 9,030 shares of the firm’s stock in a transaction that occurred on Tuesday, July 16th. The shares were sold at an average price of $30.00, for a total value of $270,900.00. Following the completion of the transaction, the president now directly owns 362,583 shares in the company, valued at $10,877,490. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Cheryl Scott sold 1,462 shares of the stock in a transaction that occurred on Friday, June 28th. The stock was sold at an average price of $28.39, for a total transaction of $41,506.18. Following the completion of the sale, the director now owns 10,098 shares in the company, valued at $286,682.22. The disclosure for this sale can be found here. 12.30% of the stock is currently owned by insiders.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.